Is Tesla Stock Fair Priced? This Analyst Thinks So

Wells Fargo analyst Colin Langan maintained Tesla Inc (NASDAQ: TSLA) with an Equal-Weight and cut the price target from 

Wells Fargo analyst Colin Langan maintained Tesla Inc (NASDAQ:TSLA) with an Equal-Weight and cut the price target from $280 to $230.

As TSLA will report Q3 EPS post-close on October 19, he forecasts a slight Q3 beat as forex headwinds offset pricing benefits. 

The Q3 likely focuses on IRA & demand, and TSLA will probably be the biggest IRA beneficiary. Therefore, the analyst raised his 2023-26 EPS by ~33% to reflect IRA benefits. 

Langan expected ~$3.1K/vehicle benefit from production tax credits for any U.S.-made battery, driving $2.8 billion in savings if TSLA maxes its ~900K U.S. footprint. 

The analyst writes that $3.75K in retail EV buyer credits serve as an effective 4-7% price cut for most TSLA buyers, which should drive higher volume. 

The benefit as timely as filling the close to 2 million units of global capacity will still be challenging at the current >$47K U.S. price point. 

The U.S. Model 3 has been available for >5 years & the Model Y for 2.5 years. 

The analyst price target reflects the output of his 3-stage DCF analysis of the core auto business, assuming a 13% WACC, 25% 5-10 year growth, 20% 11-15 year growth, and a 10% terminal growth rate. 

Langan also included $11 billion in value associated with solar and storage, insurance, and an option on the autonomous ride-share business. 

Price Action: TSLA shares traded lower by 3.87% at $213.14 on the last check Friday.

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

Around $3 Million Bet On Community Health Systems? Check Out These 3 Penny Stocks Insiders Are Buying

U.S. crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ARTW

Read More

Incyte Announced Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo; Said Patients Treated With Povorcitinib Experienced Improvements In Total Body And Facial Repigmentation

Incyte (Nasdaq: INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

INCY